Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring.

Heidbuchel H, Hindricks G, Broadhurst P, Van Erven L, Fernandez-Lozano I, Rivero-Ayerza M, Malinowski K, Marek A, Romero Garrido RF, Löscher S, Beeton I, Garcia E, Cross S, Vijgen J, Koivisto UM, Peinado R, Smala A, Annemans L.

Eur Heart J. 2015 Jan 14;36(3):158-69. doi: 10.1093/eurheartj/ehu339. Epub 2014 Sep 1.

2.

Darapladib for preventing ischemic events in stable coronary heart disease.

STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L.

N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.

3.

Edoxaban versus warfarin in patients with atrial fibrillation.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators.

N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

4.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

5.

Benefits of a quadripolar left ventricular lead in patients undergoing cardiac resynchronization therapy with underlying myocardial scar.

Hussain MA, Bhamra-Ariza P, Jacques A, Wilkinson P, Odemuyiwa O, Fluck D, Beeton I, Kaba RA.

Pacing Clin Electrophysiol. 2013 Feb;36(2):e45-7. doi: 10.1111/j.1540-8159.2011.03065.x. Epub 2011 Mar 31.

PMID:
21453333
6.

Safety and feasibility of cephalic venous access for cardiac resynchronization device implantation.

Ussen B, Dhillon PS, Anderson L, Beeton I, Hickman M, Gallagher MM.

Pacing Clin Electrophysiol. 2011 Mar;34(3):365-9. doi: 10.1111/j.1540-8159.2010.02975.x. Epub 2010 Nov 22.

PMID:
21091741
7.

Red blood cell nitric oxide as an endocrine vasoregulator: a potential role in congestive heart failure.

Datta B, Tufnell-Barrett T, Bleasdale RA, Jones CJ, Beeton I, Paul V, Frenneaux M, James P.

Circulation. 2004 Mar 23;109(11):1339-42. Epub 2004 Mar 15.

8.

Two diagnoses from one electrocardiogram.

Beeton I, Leatham E.

Postgrad Med J. 2001 Sep;77(911):604, 612-3. No abstract available.

9.

Coronary risk assessment in women.

Beeton ID, Leatham EW.

Lancet. 1999 Jul 31;354(9176):427. No abstract available.

PMID:
10437900
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk